Milestone Pharma director granted 77K stock options
Milestone Pharmaceuticals Inc. director Michael John Tomsicek received a grant of stock options covering 77,000 shares of common stock at an exercise price of $1.22 per share.
Rhea-AI Filing Summary
Milestone Pharmaceuticals Inc. director Michael John Tomsicek received a grant of stock options covering 77,000 shares of common stock at an exercise price of $1.22 per share. The options vest in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested by the date of the next annual stockholders’ meeting, as long as he continues to provide service. Following this grant, he holds 77,000 stock options directly, which are scheduled to expire on June 10, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 77,000 shares
Grant/Award
1 txn
Insider
TOMSICEK MICHAEL JOHN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 77,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 77,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Key Figures
Option grant size: 77,000 options
Exercise price: $1.22 per share
Underlying shares: 77,000 shares
+3 more
6 metrics
Option grant size
77,000 options
Stock Option (right to buy) granted to director
Exercise price
$1.22 per share
Conversion or exercise price of granted options
Underlying shares
77,000 shares
Underlying common stock tied to the option grant
Expiration date
June 10, 2036
Option expiration for this grant
Vesting start
July 10, 2026
First of twelve equal monthly vesting dates
Post-transaction options held
77,000 options
Total options directly owned after the grant
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, vesting, exercise price, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vesting financial
"This option will vest in twelve (12) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: "1.2200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Milestone Pharmaceuticals (MIST) disclose in this Form 4 filing?
Milestone Pharmaceuticals reported that director Michael John Tomsicek received a grant of stock options for 77,000 shares of common stock at a $1.22 exercise price. These options represent equity-based compensation rather than an open‑market stock purchase or sale.
How many Milestone Pharmaceuticals (MIST) options were granted to the director?
The director was granted stock options covering 77,000 shares of Milestone Pharmaceuticals common stock. This entire 77,000-share option position is reported as directly owned following the transaction, providing him potential future ownership if the options are exercised.
What is the exercise price and term of the new MIST stock options?
The granted stock options have an exercise price of $1.22 per share and are scheduled to expire on June 10, 2036. This long-dated term gives the director a multi‑year window to decide whether to exercise the options.
How do the Milestone Pharmaceuticals (MIST) options vest for the director?
The option grant will vest in twelve equal monthly installments starting July 10, 2026. According to the disclosure, the options will in any case be fully vested by the next annual stockholders’ meeting, if the director continues providing service through each vesting date.
How many Milestone Pharmaceuticals (MIST) options does the director hold after this grant?
Following this reported transaction, the director holds 77,000 stock options directly. These options relate to 77,000 underlying shares of Milestone Pharmaceuticals common stock, contingent on vesting and any future exercise decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
